Loading...

William Oh, MD, FACS

Title(s)Assistant Clinical Professor, Dean's Office
SchoolSchool of Medicine
Address155 N Fresno St
Fresno CA 93701
Phone559-499-6400
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020 Aug 07. Patel VG, Oh WK, Galsky MD. PMID: 32767764.
      View in: PubMed   Mentions:    Fields:    
    2. Lacrimal sac adenocarcinoma managed with androgen deprivation. Am J Ophthalmol Case Rep. 2020 Sep; 19:100607. Abramson DH, Fallon J, Biran N, Francis JH, Jaben K, Oh WK. PMID: 32760849.
      View in: PubMed   Mentions:
    3. Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study. Blood. 2020 Jul 02; 136(1):144-147. Tremblay D, van Gerwen M, Alsen M, Thibaud S, Kessler A, Venugopal S, Makki I, Qin Q, Dharmapuri S, Jun T, Bhalla S, Berwick S, Feld J, Mascarenhas J, Troy K, Cromwell C, Dunn A, Oh WK, Naymagon L. PMID: 32462179.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    4. CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade. JCO Precis Oncol. 2020; 4:382-392. Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. PMID: 32671317.
      View in: PubMed   Mentions:
    5. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 Apr; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 4     Fields:    
    6. Tracheomegaly among Extremely Preterm Infants on Prolonged Mechanical Ventilation. J Pediatr. 2020 03; 218:231-233.e1. Mirza H, Varich L, Sensakovic WF, Guruvadoo K, Royall I, Britt C, Vicenti R, Oh W. PMID: 31711760.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Duration of significant patent ductus arteriosus and bronchopulmonary dysplasia in extremely preterm infants. J Perinatol. 2019 12; 39(12):1648-1655. Mirza H, Garcia J, McKinley G, Hubbard L, Sensing W, Schneider J, Oh W, Wadhawan R. PMID: 31554913.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 11; 76(5):599-603. Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. PMID: 31272788.
      View in: PubMed   Mentions: 3     Fields:    
    9. Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. Mol Cancer Res. 2019 08; 17(8):1605-1612. Gong Y, Wang L, Yu H, Alpert N, Cohen MD, Prophete C, Horton L, Sisco M, Park SH, Lee HW, Zelikoff J, Chen LC, Hashim D, Suarez-Farinas M, Donovan MJ, Aaronson SA, Galsky M, Zhu J, Taioli E, Oh WK. PMID: 31221798.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    10. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019 Dec; 76(6):782-789. Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD. PMID: 31200951.
      View in: PubMed   Mentions: 1     Fields:    
    11. The evolving landscape of immunotherapy in advanced prostate cancer. Immunotherapy. 2019 07; 11(10):903-912. Patel VG, Oh WK. PMID: 31161846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Effects of Myo-inositol on Type 1 Retinopathy of Prematurity Among Preterm Infants <28 Weeks' Gestational Age: A Randomized Clinical Trial. JAMA. 2018 10 23; 320(16):1649-1658. Phelps DL, Watterberg KL, Nolen TL, Cole CA, Cotten CM, Oh W, Poindexter BB, Zaterka-Baxter KM, Das A, Lacy CB, Scorsone AM, Walsh MC, Bell EF, Kennedy KA, Schibler K, Sokol GM, Laughon MM, Lakshminrusimha S, Truog WE, Garg M, Carlo WA, Laptook AR, Van Meurs KP, Carlton DP, Graf A, DeMauro SB, Brion LP, Shankaran S, Orge FH, Olson RJ, Mintz-Hittner H, Yang MB, Haider KM, Wallace DK, Chung M, Hug D, Tsui I, Cogen MS, Donahue JP, Gaynon M, Hutchinson AK, Bremer DL, Quinn G, He YG, Lucas WR, Winter TW, Kicklighter SD, Kumar K, Chess PR, Colaizy TT, Hibbs AM, Ambalavanan N, Harmon HM, McGowan EC, Higgins RD. PMID: 30357297.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    13. The role of ketoconazole in current prostate cancer care. Nat Rev Urol. 2018 10; 15(10):643-651. Patel V, Liaw B, Oh W. PMID: 30154429.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Multimodal therapy in the treatment of metastatic prostate cancer: A case report. Urol Case Rep. 2018 Nov; 21:92-94. Omidele OO, Schiff HI, Oh W, Tewari A. PMID: 30258788.
      View in: PubMed   Mentions:
    15. A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. J Immunother Cancer. 2018 09 18; 6(1):90. Friedlander P, Wood K, Wassmann K, Christenfeld AM, Bhardwaj N, Oh WK. PMID: 30227886.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. J Clin Gastroenterol Hepatol. 2018; 2(3). Azad A, Chang P, Devuni D, Bichoupan K, Kesar V, Branch AD, Oh WK, Galsky MD, Ahmad J, Odin JA. PMID: 30637414.
      View in: PubMed   Mentions:
    17. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol. 2018 11; 36(11):500.e1-500.e9. Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP. PMID: 30201382.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018 08 29; 9(1):3503. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. PMID: 30158554.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimals
    19. Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. J Urol. 2018 12; 200(6):1264-1272. Lowrance WT, Murad MH, Oh WK, Jarrard DF, Resnick MJ, Cookson MS. PMID: 30086276.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    20. Prostate-specific antigen doubling time is a significant predictor of overall and disease-free survival in patients with prostate adenocarcinoma treated with brachytherapy. Brachytherapy. 2018 Nov - Dec; 17(6):874-881. Resende Salgado L, Rhome R, Oh W, Stone N, Stock R. PMID: 30061057.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. Oncogene. 2018 11; 37(44):5858-5872. Lee E, Collazo-Lorduy A, Castillo-Martin M, Gong Y, Wang L, Oh WK, Galsky MD, Cordon-Cardo C, Zhu J. PMID: 29970902.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    22. Prostate cancer characteristics in the World Trade Center cohort, 2002-2013. Eur J Cancer Prev. 2018 07; 27(4):347-354. Hashim D, Boffetta P, Galsky M, Oh W, Lucchini R, Crane M, Luft B, Moline J, Udasin I, Harrison D, Taioli E. PMID: 27898584.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    23. Effects of soybean lipid infusion on triglyceride and unbound free fatty acid levels in preterm infants. J Matern Fetal Neonatal Med. 2019 Oct; 32(19):3226-3231. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Joe Shih W, Carayannopoulos M, Oh W. PMID: 29618229.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCTClinical Trials
    24. Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. Onco Targets Ther. 2018; 11:2141-2147. Chong JT, Oh WK, Liaw BC. PMID: 29695920.
      View in: PubMed   Mentions:
    25. Natural History of Postnatal Cardiopulmonary Adaptation in Infants Born Extremely Preterm and Risk for Death or Bronchopulmonary Dysplasia. J Pediatr. 2018 07; 198:187-193.e1. Mirza H, Garcia JA, Crawford E, Pepe J, Zussman M, Wadhawan R, Oh W. PMID: 29625730.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Unbound bilirubin measurements by a novel probe in preterm infants. J Matern Fetal Neonatal Med. 2019 Aug; 32(16):2721-2726. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih W, Carayannopoulos M, Oh W. PMID: 29504491.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care? J Clin Oncol. 2018 04 10; 36(11):1060-1061. Tsao CK, Oh WK. PMID: 29432079.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Res. 2018 04 15; 78(8):2065-2080. McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD. PMID: 29358171.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    29. Association of intralipid intake in extremely low birthweight infants with neurodevelopmental outcomes. Acta Paediatr. 2018 Apr; 107(4):600-604. Oh W, Przystac L, McKinley L, Tucker R, McGowan EC, Vohr BR. PMID: 29274180.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2018 05; 73(5):751-759. Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. PMID: 29248319.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    31. Racial Disparities in Clinically Significant Prostate Cancer Treatment: The Potential Health Information Technology Offers. J Oncol Pract. 2018 01; 14(1):e23-e33. Bickell NA, Lin JJ, Abramson SR, Hoke GP, Oh W, Hall SJ, Stock R, Fei K, McAlearney AS. PMID: 29194001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. Cancer Invest. 2017 Nov 26; 35(10):652-661. Lieberman-Cribbin W, Galsky M, Casey M, Liu B, Oh W, Flores R, Taioli E. PMID: 29243986.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-10. Galsky MD, Shahin M, Jia R, Shaffer DR, Gimpel-Tetra K, Tsao CK, Baker C, Leiter A, Holland J, Sablinski T, Mehrazin R, Sfakianos JP, Acon P, Oh WK. PMID: 30657386.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    34. Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO Clin Cancer Inform. 2017 11; 1:1-12. Galsky MD, Diefenbach M, Mohamed N, Baker C, Pokhriya S, Rogers J, Atreja A, Hu L, Tsao CK, Sfakianos J, Mehrazin R, Waingankar N, Oh WK, Mazumdar M, Ferket BS. PMID: 30657403.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Recognizing Symptom Burden in Advanced Prostate Cancer: A Global Patient and Caregiver Survey. Clin Genitourin Cancer. 2018 04; 16(2):e411-e419. Drudge-Coates L, Oh WK, Tombal B, Delacruz A, Tomlinson B, Ripley AV, Mastris K, O'Sullivan JM, Shore ND. PMID: 29111175.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    36. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67. Friedlander P, Wassmann K, Christenfeld AM, Fisher D, Kyi C, Kirkwood JM, Bhardwaj N, Oh WK. PMID: 28807052.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    37. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting. Med Oncol. 2017 Aug 10; 34(9):160. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. PMID: 28795333.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    38. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018 02; 73(2):178-211. Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A. PMID: 28655541.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    39. Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting. Clin Genitourin Cancer. 2017 Jun 19. Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS. PMID: 28729067.
      View in: PubMed   Mentions: 1     Fields:    
    40. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539. Pomerantz MM, Spisák S, Jia L, Cronin AM, Csabai I, Ledet E, Sartor AO, Rainville I, O'Connor EP, Herbert ZT, Szállási Z, Oh WK, Kantoff PW, Garber JE, Schrag D, Kibel AS, Freedman ML. PMID: 28608931.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    41. Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2017 Apr; 9(4):287-298. Tsao CK, Liaw B, He C, Galsky MD, Sfakianos J, Oh WK. PMID: 28491148.
      View in: PubMed   Mentions:
    42. Effects of Soybean Lipid Infusion on Unbound Free Fatty Acids and Unbound Bilirubin in Preterm Infants. J Pediatr. 2017 05; 184:45-50.e1. Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih WJ, Carayannopoulos M, Oh W. PMID: 28108102.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer. 2016; 4:92. McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL. PMID: 28031820.
      View in: PubMed   Mentions: 8     Fields:    
    44. Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. Nat Rev Clin Oncol. 2017 05; 14(5):269-283. Roubaud G, Liaw BC, Oh WK, Mulholland DJ. PMID: 27874061.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    45. Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget. 2016 10 18; 7(42):68688-68707. Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh WK, Zhu J. PMID: 27626693.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    46. Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. Oncologist. 2016 12; 21(12):1414-e9. Tsao CK, Sfakianos J, Liaw B, Gimpel-Tetra K, Kemeny M, Bulone L, Shahin M, Oh WK, Galsky MD. PMID: 27742908.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    47. Disease-specific classification using deconvoluted whole blood gene expression. Sci Rep. 2016 09 06; 6:32976. Wang L, Oh WK, Zhu J. PMID: 27596246.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    48. The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. Bladder Cancer. 2016 Jul 27; 2(3):319-327. Casey MF, Wisnivesky J, Le VH, Sarpel U, Stensland KD, Oh WK, Galsky MD. PMID: 27500199.
      View in: PubMed   Mentions:
    49. Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. Bladder Cancer. 2016 Jul 27; 2(3):341-349. Leiter A, Doucette J, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Bamias A, Oh WK, Galsky MD. PMID: 27500201.
      View in: PubMed   Mentions:
    50. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. Eur Urol. 2016 11; 70(5):707-708. Tsao CK, Galsky MD, Oh WK. PMID: 27417033.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. J Clin Oncol. 2016 08 01; 34(22):2627-35. Galsky MD, Stensland K, Sfakianos JP, Mehrazin R, Diefenbach M, Mohamed N, Tsao CK, Boffetta P, Wiklund P, Oh WK, Mazumdar M, Ferket B. PMID: 27269939.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    52. A 2-Gene Panel Derived From Prostate Cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant Prostate Cancer. Prostate. 2016 09; 76(13):1160-8. Heck MM, Thalgott M, Schmid SC, Oh WK, Gong Y, Wang L, Zhu J, Seitz AK, Porst D, Höppner M, Retz M, Gschwend JE, Nawroth R. PMID: 27198487.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    53. Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol. 2016 11; 70(5):771-775. Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, Al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD. PMID: 27178450.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    54. Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. Pediatr Res. 2016 08; 80(2):209-17. Phelps DL, Ward RM, Williams RL, Nolen TL, Watterberg KL, Oh W, Goedecke M, Ehrenkranz RA, Fennell T, Poindexter BB, Cotten CM, Hallman M, Frantz ID, Faix RG, Zaterka-Baxter KM, Das A, Ball MB, Lacy CB, Walsh MC, Carlo WA, Sánchez PJ, Bell EF, Shankaran S, Carlton DP, Chess PR, Higgins RD. PMID: 27074126.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    55. Severe post-treatment leukopenia associated with the development of encephalopathy following ifosfamide infusion. Anticancer Drugs. 2016 Mar; 27(3):235-8. Kim SS, Isola LM, Oh WK. PMID: 26628483.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. J Clin Oncol. 2016 Mar 10; 34(8):825-32. Galsky MD, Stensland KD, Moshier E, Sfakianos JP, McBride RB, Tsao CK, Casey M, Boffetta P, Oh WK, Mazumdar M, Wisnivesky JP. PMID: 26786930.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    57. Effects of indomethacin prophylaxis timing on intraventricular haemorrhage and patent ductus arteriosus in extremely low birth weight infants. Arch Dis Child Fetal Neonatal Ed. 2016 Sep; 101(5):F418-22. Mirza H, Laptook AR, Oh W, Vohr BR, Stoll BJ, Kandefer S, Stonestreet BS. PMID: 26733540.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    58. Effects of Placental Transfusion on Neonatal and 18 Month Outcomes in Preterm Infants: A Randomized Controlled Trial. J Pediatr. 2016 Jan; 168:50-5.e1. Mercer JS, Erickson-Owens DA, Vohr BR, Tucker RJ, Parker AB, Oh W, Padbury JF. PMID: 26547399.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    59. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. J Vis Exp. 2015 Oct 20; (105):53182. Williams ES, Rodriguez-Bravo V, Rodriquez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. PMID: 26555435.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    60. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemother Pharmacol. 2015 Dec; 76(6):1259-65. Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. PMID: 26464352.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    61. A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. BMC Med. 2015 Aug 21; 13:201. Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R, Galsky M, Tsao CK, Schadt E, de Bono J, Olmos D, Zhu J, Oh WK. PMID: 26297150.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    62. Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. Front Oncol. 2015; 5:129. Shevach J, Gallagher EJ, Kochukoshy T, Gresia V, Brar M, Galsky MD, Oh WK. PMID: 26125012.
      View in: PubMed   Mentions:
    63. Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs? Nat Rev Clin Oncol. 2015 Jun; 12(6):316-8. Liaw BC, Oh WK. PMID: 25917253.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    64. Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy. Curr Urol Rep. 2015 Mar; 16(3):13. Liaw BC, Shevach J, Oh WK. PMID: 25677235.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. Clinical trial awareness: Changes over time and sociodemographic disparities. Clin Trials. 2015 Jun; 12(3):215-23. Leiter A, Diefenbach MA, Doucette J, Oh WK, Galsky MD. PMID: 25673636.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    66. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med. 2015 Feb; 175(2):293-5. Galsky MD, Stensland KD, McBride RB, Latif A, Moshier E, Oh WK, Wisnivesky J. PMID: 25437434.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    67. Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. J Urol. 2015 Jul; 194(1):91-7. Tsao CK, Gray KP, Nakabayashi M, Evan C, Kantoff PW, Huang J, Galsky MD, Pomerantz M, Oh WK. PMID: 25623747.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. J Urol. 2015 Jul; 194(1):36-41. Casey MF, Gross T, Wisnivesky J, Stensland KD, Oh WK, Galsky MD. PMID: 25623748.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    69. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer. Prostate. 2015 May; 75(6):616-27. Gong Y, Chippada-Venkata UD, Galsky MD, Huang J, Oh WK. PMID: 25560638.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    70. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Invest New Drugs. 2015 Apr; 33(2):397-408. Petrylak DP, Gandhi JG, Clark WR, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G. PMID: 25556680.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    71. Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). BJU Int. 2015 Jul; 116(1):17-29. Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ. PMID: 25046451.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    72. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015 Apr; 13(2):113-23. Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin ME. PMID: 25450031.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    73. Use of crowdsourcing for cancer clinical trial development. J Natl Cancer Inst. 2014 Oct; 106(10). Leiter A, Sablinski T, Diefenbach M, Foster M, Greenberg A, Holland J, Oh WK, Galsky MD. PMID: 25217580.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    74. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst. 2014 Sep; 106(9). Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, Boffetta P, Hall SJ, Oh WK, Galsky MD. PMID: 25190726.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    75. Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma. Oncologist. 2014 Sep; 19(9):915-6. Agarwal N, Apolo AB, Tsao CK, Lee KM, Godbold JH, Soto R, Poole A, Gimpel-Tetra K, Lowe N, Oh WK, Galsky MD. PMID: 25052451.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    76. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Sep; 74(3):465-71. Galsky MD, Posner M, Holcombe RF, Lee KM, Misiukiewicz K, Tsao CK, Godbold J, Soto R, Gimpel-Tetra K, Lowe N, Oh WK. PMID: 25023489.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    77. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression. Cancers (Basel). 2014 Jun 27; 6(3):1298-327. Gong Y, Chippada-Venkata UD, Oh WK. PMID: 24978435.
      View in: PubMed   Mentions:
    78. Mind the gap: efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. Cancer. 2014 Oct 01; 120(19):2944-5. Galsky MD, Oh WK. PMID: 24965362.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    79. The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Urol. 2014 Jun; 6(3):97-104. Tsao CK, Cutting E, Martin J, Oh WK. PMID: 24883107.
      View in: PubMed   Mentions:
    80. The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian J Androl. 2014 May-Jun; 16(3):331-3. Yu EY, Oh WK. PMID: 24759585.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    81. Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8. Saenger Y, Magidson J, Liaw B, de Moll E, Harcharik S, Fu Y, Wassmann K, Fisher D, Kirkwood J, Oh WK, Friedlander P. PMID: 24721645.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    82. T2 muscle-invasive bladder cancer. Semin Oncol. 2014 Apr; 41(2):e11-8. Tsao CK, Small A, Hall S, Oh WK, Galsky MD, Buckstein M, Stock R, Ali G, Morris GJ. PMID: 24787300.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. J Invest Dermatol. 2014 Aug; 134(8):2202-2211. Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM. PMID: 24522433.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    84. Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. Crit Rev Oncol Hematol. 2014 Jun; 90(3):253-61. Morgan CJ, Oh WK, Naik G, Galsky MD, Sonpavde G. PMID: 24500033.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    85. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer. Eur Urol. 2014 Aug; 66(2):184-5. Tsao CK, Galsky MD, Oh WK. PMID: 24433812.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    86. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer. Cancer. 2014 Mar 15; 120(6):833-9. Doctor SM, Tsao CK, Godbold JH, Galsky MD, Oh WK. PMID: 25302607.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    87. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014 Jan 10; 32(2):83-9. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD. PMID: 24323037.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    88. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol. 2014 Jan; 44(1):5-16. Oh WK, McDermott D, Porta C, Levy A, Elaidi R, Scotte F, Hawkins R, Castellano D, Bellmunt J, Rha SY, Sun JM, Nathan P, Feinberg BA, Scott J, McDermott R, Ahn JH, Wagstaff J, Chang YH, Ou YC, Donnellan P, Huang CY, McCaffrey J, Chiang PH, Chuang CK, Korves C, Neary MP, Diaz JR, Mehmud F, Duh MS. PMID: 24247547.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    89. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One. 2013; 8(10):e77366. Gong Y, Scott E, Lu R, Xu Y, Oh WK, Yu Q. PMID: 24143225.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimalsCells
    90. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. Urol Oncol. 2014 Jan; 32(1):48.e1-8. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Pond G, Godbold J, Oh WK, Bamias A. PMID: 24055428.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    91. Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants. J Pediatr. 2014 Jan; 164(1):34-39.e2. Stark AR, Carlo WA, Vohr BR, Papile LA, Saha S, Bauer CR, Oh W, Shankaran S, Tyson JE, Wright LL, Poole WK, Das A, Stoll BJ, Fanaroff AA, Korones SB, Ehrenkranz RA, Stevenson DK, Peralta-Carcelen M, Wilson-Costello DE, Bada HS, Heyne RJ, Johnson YR, Lee KG, Steichen JJ. PMID: 23992673.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    92. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 2014 Sep; 9(3):195-204. Gartrell BA, Ying J, Sivendran S, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Agarwal N, Galsky MD. PMID: 23852656.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. Lancet Oncol. 2013 Jul; 14(8):681-2. Galsky MD, Oh WK. PMID: 23742876.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    94. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3020-6. Galsky MD, Krege S, Lin CC, Hahn N, Ecke T, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23720197.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    95. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013 Aug 15; 119(16):3012-9. Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23720216.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    96. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014 Feb; 40(1):190-6. Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, Sonpavde G, Oh WK, Galsky MD. PMID: 23684373.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    97. The impact of gender on outcomes in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer. 2013 Sep; 11(3):346-52. Haines L, Bamias A, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Galsky MD. PMID: 23673281.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    98. Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. PMID: 23665272.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    99. New paradigms in microtubule-mediated endocrine signaling in prostate cancer. Mol Cancer Ther. 2013 May; 12(5):555-66. Mistry SJ, Oh WK. PMID: 23635655.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    100. Metabolic and toxicological considerations of newly approved prostate cancer drugs. Expert Opin Drug Metab Toxicol. 2013 Jul; 9(7):835-46. Tsao CK, Liaw B, Yee T, Galsky MD, Oh WK. PMID: 23581700.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Indomethacin prophylaxis to prevent intraventricular hemorrhage: association between incidence and timing of drug administration. J Pediatr. 2013 Sep; 163(3):706-10.e1. Mirza H, Oh W, Laptook A, Vohr B, Tucker R, Stonestreet BS. PMID: 23522865.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    102. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014 Jan; 32(1):30.e15-21. Galsky MD, Krege S, Lin CC, Hahn N, Ecke TH, Moshier E, Sonpavde G, Godbold J, Oh WK, Bamias A. PMID: 23428534.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    103. Vitamin A supplementation in extremely low-birth-weight infants: subgroup analysis in small-for-gestational-age infants. Am J Perinatol. 2013 Oct; 30(9):771-80. Londhe VA, Nolen TL, Das A, Higgins RD, Tyson JE, Oh W, Devaskar SU. PMID: 23329565.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    104. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013 Dec; 31(6):1535-9. Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 23223962.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    105. Emerging personalized approaches for the management of advanced urothelial carcinoma. Expert Rev Anticancer Ther. 2012 Dec; 12(12):1537-43. Tsao CK, Gartrell BA, Oh WK, Galsky MD. PMID: 23253220.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    106. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012 Dec 10; 30(35):4416-26. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. PMID: 23150697.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    107. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012 Dec 05; 104(23):1837-40. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. PMID: 23093559.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    108. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012 Nov; 13(11):1105-13. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK. PMID: 23059047.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    109. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int. 2012 Dec; 110(11):1580-8. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. PMID: 22985411.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    110. Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer. BJU Int. 2012 Dec; 110(11):1729-35. Nakabayashi M, Werner L, Courtney KD, Buckle G, Oh WK, Bubley GJ, Hayes JH, Weckstein D, Elfiky A, Sims DM, Kantoff PW, Taplin ME. PMID: 22928480.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    111. Atypical metastases from prostate cancer: 10-year experience at a single institution. AJR Am J Roentgenol. 2012 Aug; 199(2):367-72. Vinjamoori AH, Jagannathan JP, Shinagare AB, Taplin ME, Oh WK, Van den Abbeele AD, Ramaiya NH. PMID: 22826398.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    112. Bevacizumab treatment of prostate cancer. Expert Opin Biol Ther. 2012 Sep; 12(9):1241-9. Small AC, Oh WK. PMID: 22775507.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    113. Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. Cancer. 2012 Dec 01; 118(23):5947-54. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold JH, Smith CB, Sonpavde G, Oh WK, Galsky MD. PMID: 22707387.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    114. Spontaneous intestinal perforation in extremely low birth weight infants: association with indometacin therapy and effects on neurodevelopmental outcomes at 18-22 months corrected age. Arch Dis Child Fetal Neonatal Ed. 2013 Mar; 98(2):F127-32. Wadhawan R, Oh W, Vohr BR, Saha S, Das A, Bell EF, Laptook A, Shankaran S, Stoll BJ, Walsh MC, Higgins R. PMID: 22684157.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    115. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012 Sep; 10(3):159-63. Tsao CK, Small AC, Moshier EL, Gartrell BA, Wisnivesky JP, Sonpavde G, Godbold JH, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 22651971.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    116. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012 Nov; 38(7):919-25. Sivendran S, Liu Z, Portas LJ, Yu M, Hahn N, Sonpavde G, Oh WK, Galsky MD. PMID: 22651902.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    117. Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World J Urol. 2013 Oct; 31(5):1211-7. Small AC, Tsao CK, Moshier EL, Gartrell BA, Wisnivesky JP, Godbold J, Sonpavde G, Palese MA, Hall SJ, Oh WK, Galsky MD. PMID: 22622394.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    118. The emerging role of circulating tumor cell detection in genitourinary cancer. J Urol. 2012 Jul; 188(1):21-6. Small AC, Gong Y, Oh WK, Hall SJ, van Rijn CJ, Galsky MD. PMID: 22578722.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    119. Overcoming castration resistance in prostate cancer. Curr Opin Urol. 2012 May; 22(3):167-74. Tsao CK, Small AC, Galsky MD, Oh WK. PMID: 22472508.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    120. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes. CA Cancer J Clin. 2012 Sep-Oct; 62(5):299-308. Galsky MD, Small AC, Tsao CK, Oh WK. PMID: 22535487.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    121. Hemodynamic effects of delayed cord clamping in premature infants. Pediatrics. 2012 Mar; 129(3):e667-72. Sommers R, Stonestreet BS, Oh W, Laptook A, Yanowitz TD, Raker C, Mercer J. PMID: 22331336.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    122. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer. 2012 Oct 01; 118(19):4777-84. Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK. PMID: 22282219.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    123. The effects of aggressive vs. conservative phototherapy on the brainstem auditory evoked responses of extremely-low-birth-weight infants. Pediatr Res. 2012 Jan; 71(1):77-84. Lasky RE, Church MW, Orlando MS, Morris BH, Parikh NA, Tyson JE, McDavid GE, Oh W, Stevenson DK, Van Meurs KP, Guillet R, Phelps DL. PMID: 22289854.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    124. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer. Clin Genitourin Cancer. 2012 Mar; 10(1):15-20. Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD. PMID: 22130294.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    125. Secondary hormonal therapy in men with castration-resistant prostate cancer. Clin Genitourin Cancer. 2011 Dec; 9(2):95-103. Nakabayashi M, Werner L, Oh WK, Regan MM, Kantoff PW, Taplin ME. PMID: 21958520.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    126. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50. Sun T, Oh WK, Jacobus S, Regan M, Pomerantz M, Freedman ML, Lee GS, Kantoff PW. PMID: 21900597.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    127. Cytokines and neurodevelopmental outcomes in extremely low birth weight infants. J Pediatr. 2011 Dec; 159(6):919-25.e3. Carlo WA, McDonald SA, Tyson JE, Stoll BJ, Ehrenkranz RA, Shankaran S, Goldberg RN, Das A, Schendel D, Thorsen P, Skogstrand K, Hougaard DM, Oh W, Laptook AR, Duara S, Fanaroff AA, Donovan EF, Korones SB, Stevenson DK, Papile LA, Finer NN, O'Shea TM, Poindexter BB, Wright LL, Ambalavanan N, Higgins RD. PMID: 21798559.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    128. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology. 2011 Sep; 78(3):626-30. Oh WK, Galsky MD, Stadler WM, Srinivas S, Chu F, Bubley G, Goddard J, Dunbar J, Ross RW. PMID: 21762967.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    129. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30. Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF. PMID: 21700509.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    130. Early nutrition mediates the influence of severity of illness on extremely LBW infants. Pediatr Res. 2011 Jun; 69(6):522-9. Ehrenkranz RA, Das A, Wrage LA, Poindexter BB, Higgins RD, Stoll BJ, Oh W. PMID: 21378596.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    131. Clinical development of cabazitaxel for the treatment of castration-resistant prostate cancer. Clin Med Insights Oncol. 2011; 5:163-9. Tsao CK, Seng S, Oh WK, Galsky MD. PMID: 21695098.
      View in: PubMed   Mentions:
    132. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GS, Kantoff PW. PMID: 21606417.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    133. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol. 2011 Jun 10; 29(17):2432-8. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg CN, Bajorin DF, Bellmunt J. PMID: 21555688.
      View in: PubMed   Mentions: 72     Fields:    Translation:Humans
    134. PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 2011 Nov; 71(15):1668-79. Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ, Huang J. PMID: 21432867.
      View in: PubMed   Mentions: 86     Fields:    Translation:HumansAnimalsCells
    135. Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int. 2011 Oct; 108(7):1086-91. Misra D, Xie W, Regan MM, Ross RW, Lee GS, Germain D, Kantoff PW, Oh WK. PMID: 21410629.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    136. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28. Pomerantz MM, Werner L, Xie W, Regan MM, Lee GS, Sun T, Evan C, Petrozziello G, Nakabayashi M, Oh WK, Kantoff PW, Freedman ML. PMID: 21367958.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    137. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011 Mar; 12(3):211-4. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, Dreicer R, Vogelzang N, Sternberg C, Bajorin DF, Bellmunt J. PMID: 21376284.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    138. Neurodevelopmental outcomes of triplets or higher-order extremely low birth weight infants. Pediatrics. 2011 Mar; 127(3):e654-60. Wadhawan R, Oh W, Vohr BR, Wrage L, Das A, Bell EF, Laptook AR, Shankaran S, Stoll BJ, Walsh MC, Higgins RD. PMID: 21357334.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    139. Is phototherapy exposure associated with better or worse outcomes in 501- to 1000-g-birth-weight infants? Acta Paediatr. 2011 Jul; 100(7):960-5. Hintz SR, Stevenson DK, Yao Q, Wong RJ, Das A, Van Meurs KP, Morris BH, Tyson JE, Oh W, Poole WK, Phelps DL, McDavid GE, Grisby C, Higgins RD. PMID: 21272067.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    140. Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr. 2011 Apr; 158(4):538-42. Woo HC, Lizarda A, Tucker R, Mitchell ML, Vohr B, Oh W, Phornphutkul C. PMID: 21232766.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    141. Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int. 2011 Jan; 107(1):126-34. Abe M, Xie W, Regan MM, King IB, Stampfer MJ, Kantoff PW, Oh WK, Chan JM. PMID: 20477822.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    142. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52. Sun T, Mary LG, Oh WK, Freedman ML, Pomerantz M, Pienta KJ, Kantoff PW. PMID: 21135144.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    143. Predictors of survival in patients with prostate cancer and spinal metastasis. Presented at the 2009 Joint Spine Section Meeting. Clinical article. J Neurosurg Spine. 2010 Dec; 13(6):789-94. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. PMID: 21121759.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    144. Selective cell death mediated by small conditional RNAs: a novel therapeutic approach to cancer therapy. Asian J Androl. 2011 Mar; 13(2):181-2. Tsao CK, Oh WK. PMID: 21076441.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    145. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204. Pomerantz MM, Shrestha Y, Flavin RJ, Regan MM, Penney KL, Mucci LA, Stampfer MJ, Hunter DJ, Chanock SJ, Schafer EJ, Chan JA, Tabernero J, Baselga J, Richardson AL, Loda M, Oh WK, Kantoff PW, Hahn WC, Freedman ML. PMID: 21085629.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCells
    146. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer. 2011 Mar 15; 117(6):1172-82. Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. PMID: 21381010.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    147. Cancer therapy from bench to bedside. Mt Sinai J Med. 2010 Nov-Dec; 77(6):571-2. Oh WK, Burakoff SJ. PMID: 21105120.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    148. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2869-76. Penney KL, Pyne S, Schumacher FR, Sinnott JA, Mucci LA, Kraft PL, Ma J, Oh WK, Kurth T, Kantoff PW, Giovannucci EL, Stampfer MJ, Hunter DJ, Freedman ML. PMID: 20978177.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    149. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. Urol Oncol. 2012 Nov-Dec; 30(6):848-55. Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK. PMID: 20926319.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    150. Elevated plasma tissue inhibitor of metalloproteinase-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer. 2011 Feb 01; 117(3):517-25. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer S, Carney W, Ali SM, Kantoff PW, Lipton A. PMID: 20862742.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    151. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, Freedman ML, Kantoff PW. PMID: 20855462.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    152. Cabazitaxel. Nat Rev Drug Discov. 2010 Sep; 9(9):677-8. Galsky MD, Dritselis A, Kirkpatrick P, Oh WK. PMID: 20811375.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    153. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8. Sun T, Lee GS, Werner L, Pomerantz M, Oh WK, Kantoff PW, Freedman ML. PMID: 20615892.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    154. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec; 29(6):1465-74. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. PMID: 20499131.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    155. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. Urol Oncol. 2011 Nov-Dec; 29(6):756-63. Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antràs L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK. PMID: 20451414.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    156. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol. 2010 May; 2(3):189-207. Bellmunt J, Oh WK. PMID: 21789134.
      View in: PubMed   Mentions:
    157. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Sep; 106(6):772-8. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. PMID: 20230385.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    158. Dilemmas and controversies in the management of prostate cancer continue to present a vexing challenge to physicians and patients dealing with the disease. Preface. Urol Clin North Am. 2010 Feb; 37(1):xiii. Oh WK, Hu JC. PMID: 20152513.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology. 2010 Mar; 75(3):642-7. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. PMID: 19962733.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    160. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res. 2009 Nov 15; 15(22):7099-105. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. PMID: 19887483.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    161. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 2010 May; 105(9):1247-54. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. PMID: 19863525.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    162. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int. 2010 May; 105(10):1392-6. Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE. PMID: 19863532.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    163. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009 Dec 01; 27(34):5794-9. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. PMID: 19826129.
      View in: PubMed   Mentions: 399     Fields:    Translation:Humans
    164. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    165. Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer. 2009 Oct; 7(3):E90-2. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. PMID: 19815488.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    166. Metastatic seminoma and grade 1 follicular lymphoma presenting concurrently in a supraclavicular lymph node: a case report. Cases J. 2009 Aug 19; 2:7273. Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK. PMID: 19918516.
      View in: PubMed   Mentions:
    167. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597. Jia L, Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. PMID: 19680443.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansCells
    168. Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Curr Med Res Opin. 2009 Aug; 25(8):2081-90. Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. PMID: 19586325.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    169. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74. Pomerantz MM, Beckwith CA, Regan MM, Wyman SK, Petrovics G, Chen Y, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer MJ, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. PMID: 19549893.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    170. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009 Aug 01; 27(22):3577-83. Chan JM, Oh WK, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. PMID: 19528373.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    171. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. PMID: 19366828.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    172. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer. 2009 Mar 01; 115(5):981-7. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. PMID: 19152438.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    173. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs. 2009 Mar; 12(3):165-8. Priolo C, Oh WK, Loda M. PMID: 19333896.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    174. Twin gestation and neurodevelopmental outcome in extremely low birth weight infants. Pediatrics. 2009 Feb; 123(2):e220-7. Wadhawan R, Oh W, Perritt RL, McDonald SA, Das A, Poole WK, Vohr BR, Higgins RD. PMID: 19139085.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    175. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. PMID: 19213669.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    176. Absence of relationship between steroid hormone levels and prostate cancer tumor grade. Urology. 2009 Feb; 73(2):356-61; discussion 361-2. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. PMID: 19036418.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    177. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Urol. 2008 Dec; 5(12):650-1. Rosenberg JE, Oh WK. PMID: 18936787.
      View in: PubMed   Mentions:    Fields:    
    178. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol. 2009 Feb; 40(2):252-8. Simon RA, di Sant'Agnese PA, Huang LS, Xu H, Yao JL, Yang Q, Liang S, Liu J, Yu R, Cheng L, Oh WK, Palapattu GS, Wei J, Huang J. PMID: 18835619.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    179. Relationship between serum adiponectin and prostate cancer grade. Prostate. 2008 Oct 01; 68(14):1592-8. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee GS, Mantzoros C. PMID: 18646046.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    180. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol. 2008 Sep; 5(9):506-7. Schurko B, Oh WK. PMID: 18648352.
      View in: PubMed   Mentions: 12     Fields:    
    181. Association between urinary lactate to creatinine ratio and neurodevelopmental outcome in term infants with hypoxic-ischemic encephalopathy. J Pediatr. 2008 Sep; 153(3):375-8. Oh W, Perritt R, Shankaran S, Merritts M, Donovan EF, Ehrenkranz RA, O'Shea TM, Tyson JE, Laptook AR, Das A, Higgins RD. PMID: 18534246.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    182. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008 May; 101(9):1084-9. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. PMID: 18399827.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    183. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008 Mar 15; 112(6):1247-53. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. PMID: 18293426.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    184. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. PMID: 18281655.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    185. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer. 2008 Feb 01; 112(3):521-6. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. PMID: 18085595.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    186. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int. 2008 Feb; 101(3):308-12. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. PMID: 18184327.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    187. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int. 2008 May; 101(9):1077-83. Keating NL, O'Malley AJ, McNaughton-Collins M, Oh WK, Smith MR. PMID: 18190632.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    188. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer. 2007 Dec 15; 110(12):2709-15. Xie W, Nakabayashi M, Regan MM, Oh WK. PMID: 17960608.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    189. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res. 2007 Oct 01; 13(19):5816-24. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. PMID: 17908974.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    190. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother. 2007 Oct; 30(7):749-61. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. PMID: 17893567.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    191. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology. 2007 Sep; 70(3):527-31. Daskivich TJ, Regan MM, Oh WK. PMID: 17905110.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    192. Human milk intake and retinopathy of prematurity in extremely low birth weight infants. Pediatrics. 2007 Jul; 120(1):1-9. Heller CD, O'Shea M, Yao Q, Langer J, Ehrenkranz RA, Phelps DL, Poole WK, Stoll B, Duara S, Oh W, Lemons J, Poindexter B. PMID: 17606555.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    193. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007 Jun; 177(6):2146-50. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK. PMID: 17509304.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    194. Timing of umbilical cord clamping at birth in full-term infants. JAMA. 2007 Mar 21; 297(11):1257-8. Oh W. PMID: 17374821.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    195. The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer. 2007 Mar 15; 109(6):1090-6. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS. PMID: 17311345.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    196. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J. 2007 Mar-Apr; 13(2):125-9. Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. PMID: 17476141.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    197. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer. 2007 Feb 01; 109(3):477-86. Oh WK, Tay MH, Huang J. PMID: 17186531.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    198. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol. 2007 Feb; 196(2):147.e1-8. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK. PMID: 17306659.
      View in: PubMed   Mentions: 277     Fields:    Translation:Humans
    199. Indomethacin prophylaxis for preterm infants: the impact of 2 multicentered randomized controlled trials on clinical practice. J Pediatr. 2007 Jan; 150(1):46-50.e2. Clyman RI, Saha S, Jobe A, Oh W. PMID: 17188612.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    200. Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol. 2006 Nov; 176(5):1927-37. Daskivich TJ, Regan MM, Oh WK. PMID: 17070213.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    201. Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urol Oncol. 2006 Nov-Dec; 24(6):503-8. Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK. PMID: 17138131.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    202. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int. 2007 Jan; 99(1):22-7. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM. PMID: 16956362.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    203. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer. 2006 Sep 01; 107(5):975-81. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. PMID: 16862573.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    204. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer. 2006 Aug 01; 107(3):530-5. Michaelson MD, Kaufman DS, Kantoff P, Oh WK, Smith MR. PMID: 16804927.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    205. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006 Jun 20; 24(18):2723-8. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. PMID: 16782912.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    206. Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer. J Clin Oncol. 2006 Jun 20; 24(18):2958-9. Nakabayashi M, Bartlett RA, Oh WK. PMID: 16782932.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    207. Carboplatin for stage I seminoma. J Clin Oncol. 2006 Jun 20; 24(18):2971-2; author reply e32-3. Gilligan T, Oh WK, Kantoff PW. PMID: 16782940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    208. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer. 2006 Jun; 5(1):61-6. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. PMID: 16859581.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    209. Oral probiotics prevent necrotizing enterocolitis. J Pediatr. 2006 Jun; 148(6):849; author reply 850. Lin HC, Su BH, Oh W. PMID: 16769410.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    210. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology. 2006 Jun; 67(6):1235-40. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. PMID: 16765185.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    211. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol. 2006 May; 16(3):173-8. Daskivich TJ, Oh WK. PMID: 16679855.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    212. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms? Urology. 2006 May; 67(5):1084.e15-7. Daskivich TJ, Oh WK. PMID: 16698377.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    213. Delayed cord clamping in very preterm infants reduces the incidence of intraventricular hemorrhage and late-onset sepsis: a randomized, controlled trial. Pediatrics. 2006 Apr; 117(4):1235-42. Mercer JS, Vohr BR, McGrath MM, Padbury JF, Wallach M, Oh W. PMID: 16585320.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    214. Chemotherapy for high-risk localized prostate cancer. BJU Int. 2006 Apr; 97(4):679-83. Nakabayashi M, Oh WK. PMID: 16536752.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    215. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. PMID: 16329138.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    216. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res. 2006 Jan 01; 12(1):152-8. Febbo PG, Thorner A, Rubin MA, Loda M, Kantoff PW, Oh WK, Golub T, George D. PMID: 16397037.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    217. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics. 2006 Jan; 117(1):84-92. Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, Duara S, Poole K, Laptook A, Goldberg R. PMID: 16396864.
      View in: PubMed   Mentions: 143     Fields:    Translation:Humans
    218. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J Pediatr. 2005 Dec; 147(6):786-90. Oh W, Poindexter BB, Perritt R, Lemons JA, Bauer CR, Ehrenkranz RA, Stoll BJ, Poole K, Wright LL. PMID: 16356432.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    219. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. N Engl J Med. 2005 Oct 13; 353(15):1574-84. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, Fanaroff AA, Poole WK, Wright LL, Higgins RD, Finer NN, Carlo WA, Duara S, Oh W, Cotten CM, Stevenson DK, Stoll BJ, Lemons JA, Guillet R, Jobe AH. PMID: 16221780.
      View in: PubMed   Mentions: 577     Fields:    Translation:HumansCTClinical Trials
    220. High-risk localized prostate cancer: integrating chemotherapy. Oncologist. 2005 Oct; 10 Suppl 2:18-22. Oh WK. PMID: 16272455.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    221. Prolonged hospital stay for extremely premature infants: risk factors, center differences, and the impact of mortality on selecting a best-performing center. J Perinatol. 2005 Oct; 25(10):650-5. Cotten CM, Oh W, McDonald S, Carlo W, Fanaroff AA, Duara S, Stoll B, Laptook A, Poole K, Wright LL, Goldberg RN. PMID: 16079906.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    222. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int. 2005 Oct; 96(6):783-6. Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. PMID: 16153200.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    223. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res. 2005 Jul 15; 11(14):5233-40. Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. PMID: 16033841.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    224. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005 Jul 07; 353(1):13-22. Van Meurs KP, Wright LL, Ehrenkranz RA, Lemons JA, Ball MB, Poole WK, Perritt R, Higgins RD, Oh W, Hudak ML, Laptook AR, Shankaran S, Finer NN, Carlo WA, Kennedy KA, Fridriksson JH, Steinhorn RH, Sokol GM, Konduri GG, Aschner JL, Stoll BJ, D'Angio CT, Stevenson DK. PMID: 16000352.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    225. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J. 2005 Jul; 24(7):635-9. Stoll BJ, Hansen NI, Higgins RD, Fanaroff AA, Duara S, Goldberg R, Laptook A, Walsh M, Oh W, Hale E. PMID: 15999007.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    226. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer. 2005 Jun; 4(1):61-4. Oh WK, George DJ, Tay MH. PMID: 15992464.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    227. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. PMID: 15735119.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    228. Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2005 Jan; 115(1):1-4. Lin HC, Su BH, Chen AC, Lin TW, Tsai CH, Yeh TF, Oh W. PMID: 15629973.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCellsCTClinical Trials
    229. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 01; 11(1):284-9. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. PMID: 15671557.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    230. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J Pediatr. 2004 Dec; 145(6):832-4. Ment LR, Vohr BR, Makuch RW, Westerveld M, Katz KH, Schneider KC, Duncan CC, Ehrenkranz R, Oh W, Philip AG, Scott DT, Allan WC. PMID: 15580211.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    231. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. J Urol. 2004 Nov; 172(5 Pt 2):S34-7; discussion S37. Oh WK. PMID: 15535440.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    232. Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment. J Urol. 2004 Nov; 172(5 Pt 2):S3-5. Carroll PR, Chan JM, D'Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. PMID: 15535434.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    233. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. PMID: 15468186.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    234. Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer. Curr Treat Options Oncol. 2004 Oct; 5(5):349-55. Nakabayashi M, Oh WK. PMID: 15341673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    235. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol. 2004 Sep-Oct; 22(5):393-7. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Ye Z, Nicol SJ, Stadler WM. PMID: 15464919.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    236. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. PMID: 15289492.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    237. Plasma levels of heat shock protein 70 in patients with prostate cancer: a potential biomarker for prostate cancer. Clin Prostate Cancer. 2004 Jun; 3(1):49-53. Abe M, Manola JB, Oh WK, Parslow DL, George DJ, Austin CL, Kantoff PW. PMID: 15279691.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    238. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics. 2004 May; 113(5):1181-6. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 15121927.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    239. Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants. Pediatrics. 2004 May; 113(5):1209-15. Poindexter BB, Ehrenkranz RA, Stoll BJ, Wright LL, Poole WK, Oh W, Bauer CR, Papile LA, Tyson JE, Carlo WA, Laptook AR, Narendran V, Stevenson DK, Fanaroff AA, Korones SB, Shankaran S, Finer NN, Lemons JA. PMID: 15121931.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    240. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res. 2004 Feb 01; 10(3):924-8. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. PMID: 14871968.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    241. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology. 2004 Feb; 63(2):327-32. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, Dewolf WC, Kantoff PW, Bubley GJ. PMID: 14972483.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    242. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. PMID: 14669278.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    243. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol. 2003 Dec; 170(6 Pt 2):S3-5. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M, Sellers WR, Smith MR, McMann MC, Kantoff PW. PMID: 14610403.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    244. The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S28-32; discussion S33-4. Oh WK. PMID: 14610407.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    245. Association between peak serum bilirubin and neurodevelopmental outcomes in extremely low birth weight infants. Pediatrics. 2003 Oct; 112(4):773-9. Oh W, Tyson JE, Fanaroff AA, Vohr BR, Perritt R, Stoll BJ, Ehrenkranz RA, Carlo WA, Shankaran S, Poole K, Wright LL. PMID: 14523165.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    246. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol. 2003 Oct; 170(4 Pt 1):1305. Leibowitz SB, Oh WK. PMID: 14501750.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    247. Immediate and delayed cord clamping in infants born between 24 and 32 weeks: a pilot randomized controlled trial. J Perinatol. 2003 Sep; 23(6):466-72. Mercer JS, McGrath MM, Hensman A, Silver H, Oh W. PMID: 13679933.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    248. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology. 2003 Aug; 62(2):324-7. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. PMID: 12893344.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    249. Does labor influence neonatal and neurodevelopmental outcomes of extremely-low-birth-weight infants who are born by cesarean delivery? Am J Obstet Gynecol. 2003 Aug; 189(2):501-6. Wadhawan R, Vohr BR, Fanaroff AA, Perritt RL, Duara S, Stoll BJ, Goldberg R, Laptook A, Poole K, Wright LL, Oh W. PMID: 14520225.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    250. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology. 2003 Jul; 62(1):99-104. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. PMID: 12837431.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    251. Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. Am J Clin Oncol. 2003 Jun; 26(3):312-6. Oh WK, Kaplan ID, Febbo P, Prisby J, Manola J, Kaufman DS, Kantoff PW. PMID: 12796607.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    252. Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinoma. Cancer. 2003 May 01; 97(9):2171-9. Oh WK, Tully P, Kantoff PW, Regan MM. PMID: 12712468.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    253. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J. 2003 May-Jun; 9(3):208-12. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. PMID: 12752629.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    254. Neoadjuvant therapy before radical prostatectomy in high-risk localized prostate cancer: defining appropriate endpoints. Urol Oncol. 2003 May-Jun; 21(3):229-34. Oh WK. PMID: 12810211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    255. Neoadjuvant therapy for high-risk localized prostate cancer. Curr Oncol Rep. 2003 May; 5(3):250-7. Yu EY, Oh WK. PMID: 12667424.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    256. Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Am J Clin Nutr. 2003 Mar; 77(3):737-43. Poindexter BB, Ehrenkranz RA, Stoll BJ, Koch MA, Wright LL, Oh W, Papile LA, Bauer CR, Carlo WA, Donovan EF, Fanaroff AA, Korones SB, Laptook AR, Shankaran S, Stevenson DK, Tyson JE, Lemons JA. PMID: 12600870.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    257. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84. Oh WK, Small EJ. PMID: 12516040.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    258. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer. 2002 Nov 01; 95(9):1864-8. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. PMID: 12404279.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    259. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):1-6. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. PMID: 12231036.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    260. Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr. 2002 Sep; 141(3):370-4. Carlo WA, Stark AR, Wright LL, Tyson JE, Papile LA, Shankaran S, Donovan EF, Oh W, Bauer CR, Saha S, Poole WK, Stoll B. PMID: 12219057.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    261. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002 Sep; 60(3 Suppl 1):87-92; discussion 93. OH WK. PMID: 12231058.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    262. The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer. 2002 Sep; 1(2):81-9. Oh WK. PMID: 15046698.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    263. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002 Aug; 110(2 Pt 1):285-91. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 12165580.
      View in: PubMed   Mentions: 432     Fields:    Translation:Humans
    264. Whole-body hypothermia for neonatal encephalopathy: animal observations as a basis for a randomized, controlled pilot study in term infants. Pediatrics. 2002 Aug; 110(2 Pt 1):377-85. Shankaran S, Laptook A, Wright LL, Ehrenkranz RA, Donovan EF, Fanaroff AA, Stark AR, Tyson JE, Poole K, Carlo WA, Lemons JA, Oh W, Stoll BJ, Papile LA, Bauer CR, Stevenson DK, Korones SB, McDonald S. PMID: 12165594.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCTClinical Trials
    265. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med. 2002 Jul 25; 347(4):240-7. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. PMID: 12140299.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansCells
    266. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. Cancer. 2002 Jul 15; 95(2):275-80. D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW. PMID: 12124826.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    267. Neurodevelopmental outcome of premature infants after antenatal phenobarbital exposure. Am J Obstet Gynecol. 2002 Jul; 187(1):171-7. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, Korones SB, Stevenson DK, Donovan EF, Stoll BJ, Fanaroff AA, Oh W, Verter J. PMID: 12114906.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    268. Diluted tincture of opium (DTO) and phenobarbital versus DTO alone for neonatal opiate withdrawal in term infants. J Pediatr. 2002 May; 140(5):561-4. Coyle MG, Ferguson A, Lagasse L, Oh W, Lester B. PMID: 12032522.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    269. Risk factors for early death among extremely low-birth-weight infants. Am J Obstet Gynecol. 2002 Apr; 186(4):796-802. Shankaran S, Fanaroff AA, Wright LL, Stevenson DK, Donovan EF, Ehrenkranz RA, Langer JC, Korones SB, Stoll BJ, Tyson JE, Bauer CR, Lemons JA, Oh W, Papile LA. PMID: 11967510.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    270. Progressive sclerosis of isolated foot metastasis of prostate cancer. J Urol. 2002 Mar; 167(3):1392. Oh WK, Loda M, Kantoff PW, Janicek M. PMID: 11832744.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    271. Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. Cancer. 2002 Feb 01; 94(3):686-9. Oh WK, George DJ, Kantoff PW. PMID: 11857300.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    272. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii. Oh WK, Small EJ. PMID: 12109356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    273. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest. 2002; 20(2):186-91. Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Morrissey S, Prisby J, Kaufman DS, Shapiro CL, Kantoff PW, Smith MR. PMID: 11901538.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    William's Networks
    Concepts (787)
    Derived automatically from this person's publications.
    _
    Co-Authors (24)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _